Merck & Co., Inc. (NYSE:MRK) Shares Acquired by Gladstone Institutional Advisory LLC

Gladstone Institutional Advisory LLC lifted its position in Merck & Co., Inc. (NYSE:MRKFree Report) by 24.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 94,642 shares of the company’s stock after purchasing an additional 18,679 shares during the quarter. Gladstone Institutional Advisory LLC’s holdings in Merck & Co., Inc. were worth $10,318,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Norges Bank acquired a new stake in shares of Merck & Co., Inc. during the 4th quarter valued at about $3,108,366,000. Wellington Management Group LLP increased its position in shares of Merck & Co., Inc. by 6.7% in the third quarter. Wellington Management Group LLP now owns 82,442,666 shares of the company’s stock valued at $8,487,472,000 after buying an additional 5,196,914 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Merck & Co., Inc. by 14.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 36,682,866 shares of the company’s stock worth $3,966,029,000 after buying an additional 4,731,152 shares during the period. International Assets Investment Management LLC lifted its position in shares of Merck & Co., Inc. by 10,221.4% during the 4th quarter. International Assets Investment Management LLC now owns 2,375,269 shares of the company’s stock valued at $258,952,000 after buying an additional 2,352,256 shares in the last quarter. Finally, AEGON ASSET MANAGEMENT UK Plc acquired a new stake in Merck & Co., Inc. in the 4th quarter valued at $187,042,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Trading Up 0.2 %

Shares of NYSE MRK traded up $0.31 during mid-day trading on Friday, reaching $131.19. 8,281,595 shares of the company’s stock were exchanged, compared to its average volume of 7,287,899. The firm has a market capitalization of $332.28 billion, a price-to-earnings ratio of 145.77, a PEG ratio of 1.68 and a beta of 0.39. Merck & Co., Inc. has a 52-week low of $99.14 and a 52-week high of $133.10. The company’s 50-day moving average is $127.27 and its 200-day moving average is $118.84. The company has a debt-to-equity ratio of 0.77, a quick ratio of 0.99 and a current ratio of 1.25.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last released its quarterly earnings results on Thursday, April 25th. The company reported $2.07 EPS for the quarter, topping analysts’ consensus estimates of $1.94 by $0.13. Merck & Co., Inc. had a return on equity of 14.05% and a net margin of 3.76%. The company had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.21 billion. During the same period in the prior year, the firm earned $1.40 earnings per share. The firm’s revenue was up 8.9% compared to the same quarter last year. Analysts expect that Merck & Co., Inc. will post 8.69 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

MRK has been the topic of several research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $135.00 target price on shares of Merck & Co., Inc. in a research report on Thursday, April 18th. Barclays raised their target price on Merck & Co., Inc. from $135.00 to $145.00 and gave the company an “overweight” rating in a research report on Friday, February 2nd. StockNews.com upgraded Merck & Co., Inc. from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 2nd. Societe Generale lowered Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 price objective on the stock. in a report on Monday, March 11th. Finally, Truist Financial upped their target price on shares of Merck & Co., Inc. from $142.00 to $143.00 and gave the stock a “buy” rating in a report on Friday, April 26th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Merck & Co., Inc. presently has a consensus rating of “Moderate Buy” and a consensus price target of $131.33.

Check Out Our Latest Stock Analysis on MRK

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Further Reading

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.